Neuren Pharmaceuticals (ASX:NEU) Accounts Payable: A$0.88 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:NEU Neuren Pharmaceuticals Ltd ASX:NEU
52 GF Score
Price A$16.69
GF Value A$7.21
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Neuren Pharmaceuticals Accounts Payable?

Neuren Pharmaceuticals ASX:NEU +1.15% 52 Accounts Payable is A$0.88 Mil as of Dec. 2025. GuruFocus rates ASX:NEU with a GF Score™ of 52/100 and a GF Value™ of A$7.21 (Significantly Overvalued). The stock has 2 warning signs investors should review.

Neuren Pharmaceuticals's Accounts Payable for the quarter that ended in Dec. 2025 was A$0.88 Mil.

Neuren Pharmaceuticals's quarterly Accounts Payable increased from Dec. 2024 (A$1.45 Mil) to Jun. 2025 (A$6.66 Mil) but then declined from Jun. 2025 (A$6.66 Mil) to Dec. 2025 (A$0.88 Mil).

Neuren Pharmaceuticals's annual Accounts Payable increased from Dec. 2023 (A$0.68 Mil) to Dec. 2024 (A$1.45 Mil) but then declined from Dec. 2024 (A$1.45 Mil) to Dec. 2025 (A$0.88 Mil).

Neuren Pharmaceuticals Accounts Payable Related Terms

Neuren Pharmaceuticals Accounts Payable Historical Data

* Premium members only.

The historical data trend for Neuren Pharmaceuticals's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neuren Pharmaceuticals Accounts Payable Chart

Neuren Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.25 0.26 0.68 1.45 0.88

Neuren Pharmaceuticals Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.68 4.48 1.45 6.66 0.88
ASX:NEU
52GF Score
Neuren Pharmaceuticals Ltd ASX:NEU
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Neuren Pharmaceuticals Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of A$0.88 Mil mean?
Neuren Pharmaceuticals (ASX:NEU) has a Accounts Payable of A$0.88 Mil as of Dec. 2025. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Neuren Pharmaceuticals and its competitors.
Is Neuren Pharmaceuticals' Accounts Payable too high?
Neuren Pharmaceuticals' current Accounts Payable is A$0.88 Mil. Overall, Neuren Pharmaceuticals has a GF Score™ of 52/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Neuren Pharmaceuticals' Accounts Payable compare to VRTX and REGN?
Neuren Pharmaceuticals' Accounts Payable of A$0.88 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Biotechnology company?
A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Neuren Pharmaceuticals and its competitors. Neuren Pharmaceuticals's current Accounts Payable is A$0.88 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neuren Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Neuren Pharmaceuticals (ASX:NEU) is currently considered Significantly Overvalued. The stock's GF Value™ is A$7.21, compared to a current price of A$16.69 — trading 131.5% above its estimated fair value. The current Accounts Payable is A$0.88 Mil. Neuren Pharmaceuticals' overall GF Score™ is 52/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Neuren Pharmaceuticals (ASX:NEU), the current Accounts Payable is A$0.88 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Neuren Pharmaceuticals (ASX:NEU) Overvalued in 2026?

Based on GuruFocus' analysis, Neuren Pharmaceuticals stock appears to be overvalued. The current stock price of A$16.69 is trading 131.5% above its estimated GF Value™ of A$7.21. GuruFocus considers Neuren Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for ASX:NEU:

  • Accounts Payable: A$0.88 Mil
  • GF Value™: A$7.21 vs. price of A$16.69 (131.5% above fair value)
  • GF Score™: 52/100 with 2 warning signs

No single metric tells the full story. See the ASX:NEU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Neuren Pharmaceuticals Business Description

Other Exchanges NURPF:USANK9:Germany
Address 117 Camberwell Road, Suite 1.01, Hawthorn East, Melbourne, VIC, AUS, 3123
Neuren Pharmaceuticals Ltd is a biopharmaceutical company, which engages in the development of new therapies for brain injury, neurodevelopment disorders. Its drugs target symptoms resulting from acute traumatic brain injury, as well as symptoms of chronic conditions, such as Rett syndrome and Fragile X syndrome. The Group has two reportable operating segments, Commercial Products and Research and Development. It derives maximum revenue from Commercial Products.
52GF Score

Get the complete analysis for ASX:NEU

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$16.69
Price
A$7.21
GF Value